Evidence map›Paper›PMID 25136288›Full record

ArticleClinical proteomics2014

Proteomic profile of pre - B2 lymphoblasts from children with acute lymphoblastic leukemia (ALL) in relation with the translocation (12; 21).

Odile Costa, Pascale Schneider, Laurent Coquet, Philippe Chan, Dominique Penther, Elisabeth Legrand, Thierry Jouenne, Marc Vasse, Jean-Pierre Vannier

Open access · goldAbstract read
In one paragraph

Article in Clinical proteomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Odile CostaLaboratoire MERCI, Faculté de Médecine et de Pharmacie de Rouen, 123 boulevard Gambetta, Rouen, Cedex 76183, France.
Pascale SchneiderLaboratoire MERCI, Faculté de Médecine et de Pharmacie de Rouen, 123 boulevard Gambetta, Rouen, Cedex 76183, France ; Service d'Immuno-Hématologie Onco-pédiatrique du CHRU de Rouen, Hôpital Charles Nicolle, Rouen 76031, France.
Laurent CoquetPISSARO Proteomic facility, (IRIB), U-Rouen, Mont Saint- Aignan, France ; CNRS UMR 6270, Team « Biofilms, Résistance, Interactions Cellules-Surfaces », U-Rouen, Mont Saint-Aignan, France.
Philippe ChanPISSARO Proteomic facility, (IRIB), U-Rouen, Mont Saint- Aignan, France.
Dominique PentherLaboratoire de Cytogénétique, Centre Henri Becquerel, Rouen 76000, France.
Elisabeth LegrandLaboratoire MERCI, Faculté de Médecine et de Pharmacie de Rouen, 123 boulevard Gambetta, Rouen, Cedex 76183, France.
Thierry JouennePISSARO Proteomic facility, (IRIB), U-Rouen, Mont Saint- Aignan, France ; CNRS UMR 6270, Team « Biofilms, Résistance, Interactions Cellules-Surfaces », U-Rouen, Mont Saint-Aignan, France.
Marc VasseLaboratoire MERCI, Faculté de Médecine et de Pharmacie de Rouen, 123 boulevard Gambetta, Rouen, Cedex 76183, France.
Jean-Pierre VannierLaboratoire MERCI, Faculté de Médecine et de Pharmacie de Rouen, 123 boulevard Gambetta, Rouen, Cedex 76183, France ; Service d'Immuno-Hématologie Onco-pédiatrique du CHRU de Rouen, Hôpital Charles Nicolle, Rouen 76031, France.
Centre Henri BecquerelHôpital Charles-Nicolle · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUntil now, the major prognostic factors for pediatric acute lymphoblastic leukemia (ALL), age, white blood cell count and chromosomal alterations are initially taken into account for the risk stratification of patients. In the light of protein marker studies to classify subtypes of Acute Myeloblastic Leukemia efficiently, we have compared the lymphoblastes proteome in Childhood ALL in accordance with the presence of t(12;21), indicator of good prognosis, usually.

methodsProtein expression in pre-B2 lymphoblastic cells, collected from residual bone marrow cells after diagnostic procedures, was analyzed using two dimensional gel electrophoresis protocol. Protein spots whose average normalized volumes were statistically different in the two patients groups (n = 13; student t test p < 0.01), were excised. Tryptic peptides were then analyzed using a nano-LC1200 system coupled to a 6340 Ion Trap mass spectrometer equipped with a HPLC-chip cube interface. The tandem mass spectrometry peak lists extracted using the DataAnalysis program, were compared with the protein database Mascot Daemon.

resultsWe focused on twelve spots corresponding to sixteen identified candidate proteins among the 26 found differentially expressed (p ≤ 0.05) regarding the presence of t(12;21). Among over expressed proteins, two proteins were implicated in cellular growth arrest (i.e. calponine 2, p ≤ 0.001 and phosphatidylinositol transfer protein beta, p ≤ 0.001) in accordance with good prognosis, while two other proteins favored cell cycle proliferation (i.e. methionine adenosyl transferase 2β, p ≤ 0.005 and heterogeneous nuclear ribonucleo-proteins A2 p ≤ 0.01) and could therefore be good marker candidates of aggressiveness. Level of expression of proteasome subunit beta type-2 (p ≤ 0.01) and protein casein kinase 2α (p ≤ 0.01) which both favored apoptosis, deubiquitinating enzyme OTUB1 (p ≤ 0.05) and MLL septin-like fusion protein MSF-B, septin 9 i4 (p ≤ 0.01) were in accord with a good prognosis related to t(12;21) lymphoblasts.

conclusionBy drawing up the protein map of leukemic cells, these new data identified marker candidates of leukemic aggressiveness and new t(12;21) patients subgroups. These preliminary results will be in the near future confirmed by using a larger sample of pre-B2 childhood ALLs from national lymphoblastic cell collections.

Indexed as

BiomarkersCalponinChildhood ALLOTUB1Protein casein kinase CK2α and Ikaros

Identifiers

PMID25136288
PMCPMC4128613
OpenAlexW2123035657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.